939 related articles for article (PubMed ID: 26024975)
21. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Brzozowska MM; Ostapowicz G; Weltman MD
J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Vassilatou E
World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
[TBL] [Abstract][Full Text] [Related]
23. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
[TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism.
Bohdanowicz-Pawlak A; Lenarcik-Kabza A; Brona A; Kuliczkowska-Płaksej J; Łaczmański Ł; Zaleska-Dorobisz U; Milewicz A
Endokrynol Pol; 2014; 65(6):416-21. PubMed ID: 25554608
[TBL] [Abstract][Full Text] [Related]
25. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.
Vassilatou E; Vassiliadi DA; Salambasis K; Lazaridou H; Koutsomitopoulos N; Kelekis N; Kassanos D; Hadjidakis D; Dimitriadis G
Eur J Endocrinol; 2015 Dec; 173(6):739-47. PubMed ID: 26340970
[TBL] [Abstract][Full Text] [Related]
26. Hepatic steatosis in women with polycystic ovary syndrome.
Hong X; Guo Z; Yu Q
BMC Endocr Disord; 2023 Sep; 23(1):207. PubMed ID: 37752440
[TBL] [Abstract][Full Text] [Related]
27. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Kelley CE; Brown AJ; Diehl AM; Setji TL
World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
[TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Song DK; Jung H; Jeong K; Chung H; Lee H
Sci Rep; 2023 Aug; 13(1):13397. PubMed ID: 37591864
[TBL] [Abstract][Full Text] [Related]
29. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Macut D; Božić-Antić I; Bjekić-Macut J; Tziomalos K
Eur J Endocrinol; 2017 Sep; 177(3):R145-R158. PubMed ID: 28694246
[TBL] [Abstract][Full Text] [Related]
30. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome.
Doycheva I; Ehrmann DA
Fertil Steril; 2022 May; 117(5):897-911. PubMed ID: 35512974
[TBL] [Abstract][Full Text] [Related]
31. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
32. [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study].
Zheng RH; Ding CF
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):98-101. PubMed ID: 18683746
[TBL] [Abstract][Full Text] [Related]
33. Dietary pattern in women with polycystic ovary syndrome with and without associated non-alcoholic fatty liver disease: A cross-sectional study.
Guimarães TCM; Taranto DOL; Couto CA; Nardelli MJ; Cândido AL; Hott CA; Anastácio LR; Reis FM; Rocha ALL; Faria LC
Clinics (Sao Paulo); 2023; 78():100288. PubMed ID: 38052105
[TBL] [Abstract][Full Text] [Related]
34. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
35. Association between polycystic ovary syndrome and risk of non-alcoholic fatty liver disease: a meta-analysis.
Yao K; Zheng H; Peng H
Endokrynol Pol; 2023; 74(5):520-527. PubMed ID: 37779372
[TBL] [Abstract][Full Text] [Related]
36. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
Kumarendran B; O'Reilly MW; Manolopoulos KN; Toulis KA; Gokhale KM; Sitch AJ; Wijeyaratne CN; Coomarasamy A; Arlt W; Nirantharakumar K
PLoS Med; 2018 Mar; 15(3):e1002542. PubMed ID: 29590099
[TBL] [Abstract][Full Text] [Related]
37. [Polycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver disease].
Ciotta L; Pagano I; Stracquadanio M; Formuso C
Minerva Ginecol; 2011 Oct; 63(5):429-37. PubMed ID: 21926952
[TBL] [Abstract][Full Text] [Related]
38. Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index).
Carreau AM; Pyle L; Garcia-Reyes Y; Rahat H; Vigers T; Jensen T; Scherzinger A; Nadeau KJ; Cree-Green M
Clin Endocrinol (Oxf); 2019 Oct; 91(4):544-552. PubMed ID: 31301251
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome.
Falzarano C; Lofton T; Osei-Ntansah A; Oliver T; Southward T; Stewart S; Andrisse S
J Clin Endocrinol Metab; 2022 Jan; 107(1):258-272. PubMed ID: 34491336
[TBL] [Abstract][Full Text] [Related]
40. Ovaries are more vulnerable than hepatocytes for insulin resistance and hyperinsulinemia.
Gültepe İ; Başaranoğlu M; Süleymanoğlu Y; Başaranoğlu G; Beyazıt F
Turk J Gastroenterol; 2016 Jan; 27(1):62-7. PubMed ID: 26728862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
